Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2017
SIETES contiene 91906 citas

 
 
 1 a 20 de 896 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Messerli FH, Bangalore S, Rimoldi S, Gasowski J, Nussberger J. Are ACE inhibitors acceptable ingredients in polypills?. Lancet 2017;390:26. [Ref.ID 101670]
2. Cita con resumen
Anónimo. Drugs for hypertension. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:41-8. [Ref.ID 101527]
3.Enlace a cita originalTiene citas relacionadas
Valente M, Bhandari S. Renal function after new treatment with renin-angiotensin system blockers. BMJ 2017;356:j1122. [Ref.ID 101474]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Schmidt M, Mansfield KE, Bhaskaran K, Nitsch D, Sørensen HT, Smeeth L, Tomlinson LA. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ 2017;356:j791. [Ref.ID 101473]
5. Cita con resumen
Nardone B, Majewski S, Kim AS, Kiguradze T, Martínez-Escala EM, Friedland R, Amin A, Laumann AE, Edwards BJ, Rademaker AW, Martini MC, West DP. Melanoma and non-melanoma skin cancer associated with angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study. Drug Saf 2017;40:249-55. [Ref.ID 101451]
6. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
7. Cita con resumen
Anónimo. Spironolactone - potion or poison?. Drug Ther Bull 2017;55:13. [Ref.ID 101402]
9.Enlace a cita original
Anónimo. Sacubitril/valsartan for chronic heart failure. Australian Prescriber 2016;39:221. [Ref.ID 101024]
10. Cita con resumen
Anónimo. Sacubitril + valsartan et insuffisance cardiaque chronique. Prescrire 2016;36:645-50. [Ref.ID 100816]
11.Enlace a cita original Cita con resumen
Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Kefkowitz M, Starling R, Teerlink J, McMurray JJV, Solomon SD, for the PARADIGM-HF Investigators. Influenze of sacubitril/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. J Am Coll Cardiol 2016;68:1-8. [Ref.ID 100489]
12. Cita con resumen
Anónimo. Sacubitril valsartan for heart failure. Drug Ther Bull 2016;54:66-9. [Ref.ID 100402]
13. Cita con resumen
14.Tiene citas relacionadas Cita con resumen
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Silwa K, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Díaz R, Dans A, Dagenais G, for the HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374:2032-43. [Ref.ID 100363]
15.Tiene citas relacionadas Cita con resumen
Yusuf S, Bosch J, Dagenais G, Xavier D, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJG, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sánchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Díaz R, Lonn E, for the HOPE-3 Investigators. Cholesterol lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2021-31. [Ref.ID 100362]
16.Tiene citas relacionadas Cita con resumen
Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Pals P, Díaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Hung H, Dagenais G, Yusuf S, for the HOPE-3 Investigators. Blood-pressure lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2009-20. [Ref.ID 100361]
17.Enlace a cita original Cita con resumen
Yancy CW, Jessup M, Chair V, Bozkurt B, Butler J, Casey Jr DE, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lundenfeld JA, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westake C. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure . Circulation 2016:1-46. [Ref.ID 100318]
19. Cita con resumen
McMurray JJV, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM, for the ATHMOSPHERE Committees Investigators. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 2016;374:1521-32. [Ref.ID 100244]
20. Cita con resumen
Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B. Cardiovascular and renal outcomes of renin–angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLOS Medicine 2016:8 de marzo. [Ref.ID 100213]
Seleccionar todas
 
 1 a 20 de 896 siguiente >>